Synopsis: Update on the Re-Competition of the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC) contract, formerly the Operations and Technical Support for the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR) DATE: 11 September 2020 Purpose: The purpose of this amendment is to provide an update concerning the re-competition of the NCI FFRDC Contract, formerly the Operations and Technical Support (OTS) for the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR). The re-competition of the NCI FFRDC Contract is reinstated. This acquisition was formally suspended September 30, 2016 through notice HHS-NIH-NCI-SN-MOSB-0000-42 posted on FBO.gov. All further Special Notice Announcements pertaining to the re-competition of the NCI FFRDC Contract will be posted under Notice Number: 75N91020R00062 Additional Information: Additional information will be announced on https://beta.sam.gov/ as well as at the FNLCR Acquisition Portal: https://www.cancer.gov/about-nci/contracts/fnlcr-acquisitions/fedbizopps-notices. Please note that information posted to https://beta.sam.gov/ takes precedence over information provided elsewhere and serves as the Government’s official government-wide point of entry (GPE). All pertinent information relevant to the re-competition acquisition will be under announcement Notice Number: 75N91020R00062, and archived information is for reference only and not applicable to the current acquisition. If you have questions, please email the FNLCR Acquisition Team at:
[email protected] (
[email protected]). THIS IS A SPECIAL NOTICE. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this Special Notice is to provide an update concerning the re-competition of the NCI FFRDC contract, formerly the Operations and Technical Support contract for the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR).